Related Experiment Video
Updated: Jun 28, 2026
07:48
Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis
Published on: January 7, 2019
Determining glioma response to radiation therapy using recombinant peptides
Roberto Diaz1, Ralph J Passarella, Dennis E Hallahan
1Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. roberto.diaz@vanderbilt.edu
Expert Review of Anticancer Therapy
|November 6, 2008
Summary
New peptide ligands can noninvasively assess glioma response to radiotherapy within 24 hours, enabling faster treatment adjustments. This method offers a significant improvement over traditional tumor volume measurements and biopsies for monitoring cancer therapy effectiveness.
Area of Science:
- Oncology
- Radiotherapy
- Molecular Imaging
Background:
- Current cancer response assessment relies on imaging tumor volumes or biopsies, which are inefficient and invasive.
- Tumor volume changes require prolonged treatment, and brain tumor biopsies are difficult to perform repeatedly.
- Delayed reassessment of therapy response (2 months) can lead to prolonged ineffective treatment.
Purpose of the Study:
- To develop a rapid, noninvasive method for assessing glioma response to radiotherapy.
- To identify peptide ligands capable of differentiating between responding and resistant gliomas.
- To enable early modification or switching of ineffective cancer therapies.
Main Methods:
- Selection of peptide ligands from phage-displayed peptide libraries.
- Labeling identified peptide ligands with internal emitters for imaging.
- Noninvasive assessment of glioma susceptibility to radiotherapy within 24 hours post-therapy.
Main Results:
- Peptide ligands rapidly differentiate responding from resistant gliomas.
- Labeled peptides allow for noninvasive assessment of glioma response to radiotherapy.
- This method provides glioma response data within 24 hours of therapy initiation.
Conclusions:
- Peptide-based imaging offers a rapid, noninvasive method for monitoring glioma response to radiotherapy.
- This platform technology can significantly shorten the time to reassess cancer therapy effectiveness.
- Early detection of treatment response or resistance allows for timely therapeutic modifications, improving patient outcomes.
